Noramco of Delaware

DuPont, established in 1802 as an explosives company, offers a wide range of products for markets, including food and nutrition, health care, apparel, safety and security, construction, electronics, and transportation. The company s agriculture and nutrition segment offers hybrid seed corn and soybean seed, herbicides, fungicides, insecticides, and soy protein. Its coatings and color technologies segment provides automotive finishes, industrial coatings and white pigments. The firm s electronic and communication technologies segment offers fluorochemicals, fluoropolymers, photopolymers and electronic materials. The performance materials segment provides engineering polymers, packaging and industrial polymers, films, and elastomers. The safety and protection segment provides specialty and industrial chemicals, nonwovens, aramids, and solid surfaces. Charles O. Holliday Jr. has been the chief executive officer of EI du Pont de Nemours for more than eight years. He has been with the diversified chemical company for over 36 years. Holliday earned a BSIE from the University of Tennessee-Knoxville. DuPont is a Fortune 500 company, and is headquartered in Wilmington, Del. It operates more than 40 research and development and customer service laboratories in the United States, and over 35 laboratories in other countries.

PhaseBio Pharmaceuticals, located in Malvern, PA, is dedicated to developing innovative therapies for cardiovascular diseases, which currently affect one in four individuals. The company aims to address the pressing need for new treatment options by leveraging high-quality science and the expertise of its team to create a unique pipeline of medicines. Committed to improving patient outcomes and enhancing the healthcare system, PhaseBio focuses on overcoming the challenges associated with serious cardiovascular conditions. Their mission underscores a determination to deliver specialized therapies that can provide superior results for patients in need. Generated from the website

Paratek Pharmaceuticals, based in King Of Prussia, PA, is a biopharmaceutical company dedicated to addressing the critical global public health issue of antimicrobial resistance (AMR). Their FDA-approved tetracycline class antibiotic, Nuzyra, is designed to treat adult patients with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible bacteria. With a disciplined team of innovative professionals, Paratek is committed to developing and commercializing new treatment options for complex medical issues, including combating the ongoing pandemic of AMR. Led by CEO Evan Loh, M.D., the company strives to provide life-saving solutions to defeat superbugs and improve public health and national security. Generated from the website